Video

Dr. Gitlitz Discusses the Genomics of Young Lung Cancer Study

Barbara J. Gitlitz, MD, from the University of Southern California, discusses results and key takeaways from The Genomics of Young Lung Cancer Study.

Barbara J. Gitlitz, MD, associate professor of clinical medicine, Keck School of Medicine, University of Southern California, discusses results and key takeaways from The Genomics of Young Lung Cancer Study.

This study showed that it is feasible to think outside the box when considering patient recruitment. In this study, researchers used social media and the Internet to recruit patients. In total, Gitlitz says, 44% of patients came through these means.

Researchers greatly exceeded their statistical expectations, Gitlitz says. For patients with lung adenocarcinoma, researchers set a bar close to the Lung Cancer Mutation Consortium and wanted to demonstrate an increase in actionable mutations from 35% to 50%. In actuality, they found actionable mutations in 76% of patients.

<<<

View more from the 2015 World Conference on Lung Cancer

Related Videos
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for NVL-655 in ALK-positive NSCLC and other ALK-positive solid tumors.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss testing for ALK-positive and ROS1-positive non–small cell lung cancer.
Nicolas Girard, MD
Sally Lau, MD